Patents by Inventor Robert S. Weinstein

Robert S. Weinstein has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • In vitro and in vivo models for screening compounds to prevent glucocorticoid-induced bone destruction
    Publication number: 20040248078
    Abstract: The present invention demonstrates that glucocorticoid-induced bone disease is due to changes in the birth and death rate of bone cells using a murine model of glucocorticoid excess as well as bone biopsy specimens obtained from patients with glucocorticoid-induced osteoporosis. This invention demonstrates that glucocorticoid administration increases apoptosis of mature osteoblasts and osteocytes and decreases bone formation rate and bone mineral density accompanied by defective osteoblastogenesis and osteoclastogenesis in the bone marrow.
    Type: Application
    Filed: December 8, 2003
    Publication date: December 9, 2004
    Applicant: Board of Trustees of the University of Arkansas
    Inventors: Stavros C. Manolagas, Robert L. Jilka, Robert S. Weinstein, Teresita Bellido
  • Methods of screening for apoptosis-controlling agents for bone anabolic therapies and uses thereof
    Publication number: 20040224884
    Abstract: The invention as disclosed provides a method to increase bone mass without compromising bone strength or quality, through the administration to a host of a compound that binds to the estrogen or androgen receptor without causing hormonal transcriptional activation.
    Type: Application
    Filed: December 22, 2003
    Publication date: November 11, 2004
    Inventors: Stavros C. Manolagas, Robert L. Jilka, Robert S. Weinstein, Teresita Bellido
  • Vitro and in vivo models for screening compounds to prevent glucocorticoid-induced bone destruction
    Patent number: 6660468
    Abstract: The present invention demonstrates that glucocorticoid-induced bone disease is due to changes in the birth and death rate of bone cells using a murine model of glucocorticoid excess as well as bone biopsy specimens obtained from patients with glucocorticoid-induced osteoporosis. This invention demonstrates that glucocorticoid administration increases apoptosis of mature osteoblasts and osteocytes and decreases bone formation rate and bone mineral density accompanied by defective osteoblastogenesis and osteoclastogenesis in the bone marrow.
    Type: Grant
    Filed: October 7, 1999
    Date of Patent: December 9, 2003
    Assignee: Board of Trustees of the University of Arkansas
    Inventors: Stavros C. Manolagas, Robert L. Jilka, Robert S. Weinstein, Teresita Bellido